A clinical and genetic overview of 18 years neurofibromatosis type 1 molecular diagnostics in the Netherlands

Rick van Minkelen, Yolande Bever, Joan Kromosoeto, Caroline Hermans, Anja Nieuwlaat, Dicky Halley, Ans van den Ouweland

Research output: Contribution to journalArticleAcademicpeer-review

66 Citations (Scopus)


NF1 mutations are the underlying cause of neurofibromatosis type 1 (NF1), a neuro-cardio-facio-cutaneous syndrome (NCFC). Because of the clinical overlap between NCFCs, genetic analysis of NF1 is necessary to confirm a clinical diagnosis NF1. This report describes the clinical and genetic findings of 18years of NF1 molecular diagnostics in the Netherlands. A pathogenic mutation was found in 59.3% (1178/1985) of the index patients, mostly de novo (73.8%). The majority of the index patients (64.3%) fulfilled the National Institute of Health NF1 criteria, a pathogenic mutation was found in 80.9% of these patients. Seventy-four percent of the index patients with an NF1 pathogenic mutation and not fulfilling the NF1 criteria is <12years, in agreement with the fact that some NF1 symptoms appear after puberty. Genotype-phenotype correlations were studied for 527 index patients. NF1 patients with a type 1 microdeletion have a sixfold higher risk of special education vsNF1 patients with an intragenic mutation. No evidently milder NF1 phenotype for patients with a missense mutation was observed. Forty-six prenatal analyses were performed in 28 (2.4%) families, of which 29 (63%) showed heterozygosity for the familial pathogenic mutation. This indicates that there is a need for prenatal NF1 testing.
Original languageUndefined/Unknown
Pages (from-to)318-327
Number of pages10
JournalClinical Genetics
Issue number4
Publication statusPublished - 2014

Research programs

  • EMC MGC-02-96-01

Cite this